PRO-C9
A fragment of the NC1 domain of type IX FACIT collagen, enabling non-invasive monitoring of extracellular matrix remodeling in various solid tumors.
Key features and values
- Quantifies NC1 domain fragments of type IX collagen associated with extracellular matrix remodeling.
- Reflects changes in the extracellular matrix dynamics in various solid tumors.
- Provides a non-invasive measure of extracellular matrix turnover in oncology research.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on cancers characterized by aberrant extracellular matrix turnover.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation in cancer.
- Complements other biomarkers for a comprehensive assessment of tumor microenvironment dynamics.
Description
The PRO-C9 biomarker assay measures specific fragments of the NC1 domain of type IX collagen, serving as an indicator of extracellular matrix remodeling in various solid tumors. This non-invasive assay provides insights into tissue remodeling processes associated with cancer progression. By quantifying type IX collagen degradation products, the PRO-C9 assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tumor stroma remodeling. It serves as a valuable tool in research settings for assessing the dynamics of extracellular matrix turnover in oncology.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
